Every material Form 8-K P3 Health Partners Inc. has filed with the SEC since July 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On September 8, 2026, P3 Health Partners entered a Securities Purchase Agreement with affiliates of CPF to issue up to $70 million of units in multiple tranches, each including Series D-1 19.5% Cumulative Preferred Stock and warrants. A special committee of independent directors approved the deal because the CPF affiliates may be related parties. The preferred stock ranks senior to common stock, and the warrants could add to the number of common shares outstanding.
Up to $70 million of units to be issued in multiple tranches under a Securities Purchase Agreement dated September 8, 2026.
Series D-1 preferred stock: 19.5% cumulative dividend, $100 stated value per share, not convertible, no voting rights, redeemable at $100 per share plus unpaid dividends.
Warrants exercisable for 0.66333% of outstanding Class A and Class V common stock per $1,000,000 funded, with a seven-year term.
CPF may designate one additional independent director while it owns 40% of common stock; the 49.99% standstill limit is extended from January 1, 2027 to December 31, 2027.
P3 Health Partners reported second quarter 2026 total revenue of $386 million, up 9% from a year earlier, and net income of $15.7 million, compared with a net loss of $43.7 million in the prior-year quarter. The company raised its full-year 2026 adjusted EBITDA guidance to $80 million to $110 million, but the quarter includes favorable payer settlements and prior-year development, and at-risk membership fell 10% year over year.
Q2 2026 net income was $15.7 million, versus a net loss of $43.7 million in Q2 2025.
Q2 2026 adjusted EBITDA was $54.4 million, versus a loss of $17.1 million a year earlier.
Medical margin was $97.8 million for the quarter; excluding payer settlements and prior-year development, it was $52.9 million.
Full-year 2026 guidance: total revenue $1.5 billion to $1.6 billion; adjusted EBITDA $80 million to $110 million.
P3 Health Partners' subsidiary amended a repurchase promissory note held by IHC Health Services, extending its maturity to September 30, 2028. From June 30, 2026, the note accrues payment-in-kind (PIK) interest at 14% per year, meaning interest is added to the balance rather than paid in cash. The filing does not state the note's principal amount, so the size of the added debt cannot be determined from this document.
Amendment dated June 30, 2026, between P3 Health Group, LLC and IHC Health Services, Inc.
Maturity extended to September 30, 2028.
PIK interest at 14% per annum accrues from June 30, 2026.
Other note terms remain unchanged; the full amendment is filed as Exhibit 10.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every P3 Health Partners Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →